IRIDEX (NasdaqCM:IRIX) Q4 2025 Earnings call March 26, 2026 05:00 PM ET Company ParticipantsPatrick Mercer - President and CEOPhilip Taylor - Principal and Investor Relations Contact of IRIDEXRomeo Dizon - CFOConference Call ParticipantsScott Henry - Managing Director and Senior Research AnalystOperatorThank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q4 2025 IRIDEX earnings conference call. All lines have been placed ...

IRIDEX (NasdaqCM:IRIX) Q4 2025 Earnings call March 26, 2026 05:00 PM ET Company ParticipantsPatrick Mercer - President and CEOPhilip Taylor - Principal and Investor Relations Contact of IRIDEXRomeo Dizon - CFOConference Call ParticipantsScott Henry - Managing Director and Senior Research AnalystOperatorThank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q4 2025 IRIDEX Earnings Conference call. All lines have been placed ...

IRIDEX (NasdaqCM:IRIX) Q4 2025 Earnings call March 26, 2026 05:00 PM ET Speaker0Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q4 2025 IRIDEX Earnings Conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you'd like to ask a question during this time, simply press star followed by 1 on your telephone keypad. I ...

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational EfficienciesMOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated tot ...

MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company’s management team will host a corresponding conference call begi ...

Core Viewpoint - Iridex Corporation plans to relocate its headquarters from Mountain View, California to San Jose, California, aiming to achieve significant cost savings and maintain operational efficiency [1][3]. Cost Savings - The company signed a non-binding letter of intent for a new lease on January 26, 2026, for a 31,000 square feet location, expecting to save approximately $0.4 million in fiscal year 2026 and about $0.6 million annually thereafter [2]. - The relocation is part of the company's commitment to reducing operating expenses, which has been a priority over the past year [3]. Operational Strategy - The move is expected to lower operating expenses while allowing the company to maintain reduced manufacturing operations and attract high-caliber talent in the Bay Area [3]. - Iridex Corporation is recognized as a leader in developing and marketing innovative laser-based medical systems for the ophthalmology market, with a focus on treating glaucoma and retinal diseases [4].

Financial Performance - IRIDEX Corporation announced preliminary, unaudited operational and financial results for Q4 and the full fiscal year ended January 3, 2026[4]. - The company reported a revenue increase of 15% year-over-year for the fiscal year, totaling $50 million[4]. - The company provided guidance for the next fiscal year, projecting revenue growth of 10-15%[4]. User Growth - User data showed a growth in active users by 20%, reaching 1.2 million by the end of the fiscal year[4]. Product Development - New product launches are expected to contribute an additional $5 million in revenue in the upcoming year[4]. - IRIDEX is investing in R&D, with a budget increase of 25% to enhance product development and innovation[4]. Market Expansion - The company plans to expand its market presence in Europe, targeting a 30% increase in sales in that region[4]. - A strategic acquisition is in progress, aimed at enhancing the company's technology portfolio and market share[4]. Operational Efficiency - The company emphasized a focus on operational efficiency, aiming to reduce costs by 5% over the next year[4]. Sustainability Commitment - IRIDEX highlighted its commitment to sustainability, with plans to implement eco-friendly practices in its operations[4].

Core Insights - Iridex Corporation demonstrated continued revenue growth, operational efficiencies, and positive cash flow in its preliminary unaudited results for Q4 and full year 2025 [1][4] Fourth Quarter 2025 Results - Total revenue is expected to be between $14.6 million and $14.8 million, representing year-over-year growth of 15% to 17% compared to $12.7 million in the prior year quarter [8] - The company achieved positive cash flow in the fourth quarter [8] - Sold 15,800 Cyclo G6 probes, an increase from 13,300 in the prior year quarter [8] - Sold 44 Cyclo G6 Glaucoma Laser Systems, slightly down from 47 in the prior year quarter [8] Full Year 2025 Results - Total revenue is expected to be between $52.5 million and $52.7 million, reflecting year-over-year growth of 8% compared to $48.7 million in 2024 [8] - The company expects to achieve positive adjusted EBITDA for the full year 2025 [8] - Sold 57,700 Cyclo G6 probes, an increase from 55,400 in the prior year [8] - Sold 133 Cyclo G6 Glaucoma Laser Systems, up from 125 in the prior year [8] Company Overview - Iridex Corporation is a leader in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market [5] - The company's proprietary MicroPulse technology offers safe and effective treatment for sight-threatening eye conditions [5]

Core Viewpoint - Zacks Investment Research has initiated coverage of IRIDEX Corporation (IRIX) with a Neutral recommendation, highlighting the company's strategic transformation amidst financial and operational improvements, while also noting lingering structural challenges [1] Financial Performance - Iridex has strengthened its financial foundation with a $10 million capital infusion, eliminating prior debt and increasing working capital to $11.7 million, which includes $5.6 million in cash [2] - For the first nine months of 2025, revenues increased by 5.5% to $38 million, with significant contributions from international markets, particularly the Netherlands, which accounted for nearly 16% of revenues [3] - Operating expenses decreased by 25% in the first nine months of 2025, leading to a reduction in net loss to $4.3 million from $8.1 million a year ago [4] Industry Dynamics - The demand for ophthalmic treatments is rising globally due to an aging population and increasing prevalence of chronic eye conditions, aligning with Iridex's technologies that support minimally invasive procedures [5] Challenges - Gross margin has compressed to 36.2% from 38.7%, and a $0.8 million inventory write-down in Q3 2025 indicates ongoing demand forecasting issues [6] - A 37% reduction in research and development spending may hinder innovation and competitiveness in the medtech landscape [6] - Iridex relies heavily on its distribution agreement with Topcon Corporation, which accounted for 32% of revenues, introducing concentration risk and limiting pricing flexibility [7] Market Sentiment - Iridex's share price has shown positive momentum, indicating renewed investor interest, although its valuation remains below industry norms due to execution risks and customer concentration concerns [8]

Summary of IRIDEX Conference Call - December 11, 2025 Company Overview - **Company**: IRIDEX (NasdaqCM:IRIX) - **Industry**: Ophthalmic laser technology - **Mission**: To transform laser-based eye care for patients with ophthalmic conditions globally, focusing on innovative, non-invasive laser technologies for glaucoma and retinal disorders [3][4] Key Financials - **2024 Revenue**: $49 million, with $28 million from retina products - **Margins**: Glaucoma business at 71%, retina business at 41% [4] Product Portfolio - **Retina Products**: Comprehensive portfolio including Pascal and IQ platforms, MicroPulse technology, and disposable probes, catering to surgical and medical retina needs [4][6] - **Glaucoma Products**: CycloG6 platform and MicroPulse TLT gaining traction for their safety and predictability in treatment [5][10] Market Dynamics - **Retina Market**: Over 8 million procedures annually, with a growing demand due to diabetic eye disease and aging populations [7] - **Glaucoma Market**: Estimated $700 million market outside the U.S., with significant growth potential in moderate and mild patients [10][11] Clinical Evidence - **MicroPulse Technology**: Demonstrated greater than 50% IOP reduction with excellent safety profile, repeatable treatments showing sustained results over time [13][20] - **DAME Trial**: Aims to extend visual acuity in DME patients while addressing economic burdens of repeated pharmaceutical injections [7] Operational Changes - **Cost Management**: Reduced operating expenses by $2.3 million, achieved positive adjusted EBITDA, and plans for cash flow positivity in Q4 2026 [18][19] - **Sales Strategy**: Streamlined sales team from 13 to 6, focusing on effective targeting using MedScout for better access to clinicians [21][22] Future Outlook - **Growth Opportunities**: Replacement of aging retina systems (40-50% nearing end of life) and expansion in glaucoma treatments [6][23] - **Manufacturing Strategy**: Transitioning to contract manufacturing to improve margins by 350 to 500 basis points by FY26 [31] Competitive Landscape - **Competitors**: Competes with incisional procedures and pharmaceuticals in glaucoma, and other laser companies in retina [25][26] - **Market Share**: Gained share in glaucoma, steady growth in retina business [26] Reimbursement and Financial Health - **Stable Reimbursement**: No anticipated changes to current CPT codes affecting probe utilization [34] - **Cash Position**: $5.6 million cash balance at the end of Q3, with improved cash flow management [36] Conclusion - **Company Transformation**: IRIDEX is positioned for growth with a focus on operational efficiency, innovative product offerings, and a strong clinical foundation, aiming to prove its value to investors over the next 12 months [42][43]